National Academies Press: OpenBook

Priorities for the National Vaccine Plan (2010)

Chapter: Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)

« Previous: Appendix E: History of Public Engagement at the National Vaccine Program Office
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Appendix F
Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)

FIRST NATIONAL STAKEHOLDER MEETING VACCINE SUPPLY AND USE

Thursday, July 24, 2008

University of Chicago Gleacher Center, Room 300

Chicago, Illinois

8:15 – 8:30 am

Welcome and Committee Introductions

Claire V. Broome

Institute of Medicine (IOM) Committee Chair

8:30 – 9:45 am

Childhood immunization schedule

Melinda Wharton

Deputy Director

National Center for Immunizations and Respiratory Diseases (NCIRD)

Centers for Disease Control and Prevention (CDC)

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Alternative venues for immunization (adolescent and adult)

Gina Mootrey

Associate Director for Adult Immunization

Immunization Services Division

National Center for Immunization and Respiratory Diseases

Coordinating Center for Infectious Diseases

Centers for Disease Control and Prevention

 

Incentives and requirements (across the lifespan)

Lance Rodewald

Director

Immunization Services Division

National Center for Immunization and Respiratory Diseases

Coordinating Center for Infectious Diseases

Centers for Disease Control and Prevention

 

Surveillance and monitoring

Anne Schuchat

RADM, U.S. Public Health Service (PHS)

Director, National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

9:45 – 10:00 am

Committee questions

10:00 – 10:45 am

Panel: Surveillance and information systems

Mike Garcia

Vice President and Chief Operations Officer

Scientific Technologies Corporation

 

Christine Hahn

Idaho State Epidemiologist

Department of Health and Welfare

 

Discussant:

Emily Peterson

Coordinator, Immunization Information Systems

Minnesota Department of Health

10:45 – 11:15 am

Committee questions and discussion

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

11:15 – 11:45 am

Achieving better use of vaccines

Gregory A. Poland

Director

Vaccine Research Group

Mayo Clinic

11:45 am – 12:00 pm

Committee questions and discussion

12:00 – 1:00 pm

Lunch

1:00 – 2:00 pm

Panel: Access to immunization services

Jeffrey Duchin

Chief, Communicable Disease Control

Epidemiology and Immunization Section Public Health—Seattle & King County

 

Mitchel Rothholtz

Chief of Staff

American Pharmacists Association

 

Carl Toren

Medical Director

Chicago Family Health Center

 

Discussants:

Lyle J. Fagnan

Director,

Oregon Rural Practice-Based Research Network

Associate Professor of Family Medicine

Oregon Health and Science University

Representative, American Academy of Family Practice

 

Cheryl A. Peterson

Senior Policy Fellow

Department of Nursing Practice and Policy

American Nurses Association

2:00 – 2:30 pm

Committee questions and discussion

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

2:30 – 3:10 pm

Vaccine finance: Overview of stakeholder input and NVAC working group draft white paper

Walter Orenstein

National Vaccine Advisory Committee (NVAC)

Vaccine Finance Working Group

Associate Director, Emory Vaccine Center

Director, Emory Program for Vaccine Policy and Development

Emory University

 

Discussants:

Ann Clemency Kohler

Executive Director

National Association of State Medicaid Directors

 

Alan Rosenberg

Vice President

Wellpoint, Inc.

Representative, America’s Health Insurance Plans

3:10 – 3:30 pm

Committee questions and discussion

3:30 – 3:45 pm

Break

3:45 – 4:15 pm

Panel: Provider knowledge and practice

George Isham

Chief Health Officer

Health Partners

 

Allison Kempe

Professor of Pediatrics

Director, Primary Care Research Fellowship

Director, Children’s Outcomes Research Program

University of Colorado at Denver Health Sciences Center

 

Julie Morita

Medical Director

Immunization Program

Chicago Department of Public Health

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Discussants:

Lyle J. Fagnan

Director, Oregon Rural Practice-Based Research Network

Associate Professor of Family Medicine

Oregon Health and Science University

Representative, American Academy of Family Practice

 

Wayne Hachey

Director, Preventive Medicine and Surveillance

Office of the Assistant Secretary of Defense (Health Affairs) Force Health Protection and Readiness

Department of Defense

4:15 – 4:45 pm

Committee questions and discussion

4:45 – 5:45 pm

Panel: Vaccine supply

Norman W. Baylor

Office of Vaccines Research and Review

Center for Biologics Evaluation and Research (CBER)

Food and Drug Administration (FDA)

 

Laurel Wood

Manager

Immunization Program

Alaska Department of Health and Social Services

Chair

Association of Immunization Managers

 

Discussants:

Marguerite D. Baxter

Vice President and Head, Global Public Affairs Novartis Vaccines and Diagnostics, Inc.

 

Isabelle Claxton

Director

Public Policy and Advocacy

GSK Vaccines

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

John D. Grabenstein

Senior Director, Adult Vaccine Medical Affairs

Merck Vaccines & Infectious Diseases

 

Gregory S. Wallace

Chief, Vaccine Supply & Assurance Branch

Immunization Services Division

National Center for Immunization & Respiratory Diseases

Centers for Disease Control and Prevention

5:45 – 6:15 pm

Committee questions and discussion

6:15 – 6:30 pm

Public comment

SECOND NATIONAL STAKEHOLDER MEETING DEVELOPMENT OF NEW AND IMPROVED VACCINES

Monday, December 1, 2008

Huntington Room, Arnold and Mabel Beckman Center

100 Academy Drive

Irvine, California


Please note:

Panelist titles and affiliations are provided at the end of the agenda.

(*) denotes panelists who will give a formal presentation

() denotes panelists who contributed to the draft National Vaccine Plan

8:30 am

Welcome and Committee Introductions

Claire V. Broome

Institute of Medicine (IOM)

Committee Chair

8:45 – 10:15 am

Panel 1: Encouraging scientific innovation (new vaccines, better vaccines)

Moderator: Milagritos Tapia (IOM committee member)

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Panelists:

Philip Dormitzer (Novartis)

Kathryn Edwards (Vanderbilt University)

Emil Gotschlich (Rockefeller University)

Harry Greenberg (Stanford University)

Diane Griffin (Johns Hopkins University)

Ed Mocarski* (MedImmune)

Barbara Mulach(National Institutes of Health [NIH]/National Institute of Allergy and Infectious Diseases [NIAID])

Stanley Plotkin* (Sanofi)

Robin Robinson(HHS/BARDA)

Rebecca Sheets(NIH/NIAID) (via video)

Justin Wright (BD Medical-Pharmaceutical Systems)

10:15 – 10:30 am

Break

10:30 – 11:15 am

Panel 1 continued

11:15 am – 12:30 pm

Panel 2: Financing vaccine research and development

Moderator: Claire V. Broome (IOM Committee Chair)

 

Panelists:

Harry B. Greenberg (Stanford University)

Karl D. Handelsman (CMEA Ventures)

David C. Kaslow (Merck)

Leighton Read* (Alloy Ventures)

Jeffrey Ulmer (Novartis)

12:30 – 1:30 pm

Lunch

1:30 – 3:00 pm

Panel 3: Addressing public needs and priorities

Moderator: Edgar Marcuse (IOM committee member)

 

Panelists:

Philip R. Dormitzer (Novartis)

Kathryn Edwards (Vanderbilt University)

David C. Kaslow (Merck)

Edward Mocarski (MedImmune)

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Stanley A. Plotkin* (Sanofi)

Robin Robinson(HHS/BARDA)

3:00 – 3:15 pm

Break

3:15 – 4:30 pm

Panel 4: Regulatory and other issues in developing and licensing novel processes, new technologies, etc.

Moderator: Arthur Reingold (IOM committee member)

 

Panelists:

Karl D. Handelsman (CMEA Ventures)

David C. Kaslow (Merck)

Karen Midthun (FDA/CBER)

Leighton Read (Alloy Ventures)

Rebecca Sheets(NIH/NIAID) (via video)

Jeffrey Ulmer (Novartis)

4:30 – 5:30 pm

Closing dialogue

Moderator: Claire V. Broome (IOM committee chair)

Question to all stakeholders at the meeting: What criteria would you use to determine what objectives should receive the greatest level of attention in the National Vaccine Plan?

Final observations about the day’s discussions All panelists and audience members

5:30 pm

Adjourn

PANELIST TITLES AND AFFILIATIONS

Philip Dormitzer

Senior Director and Senior Project Leader (viral vaccine research)

Novartis Vaccines and Diagnostics


Kathryn Edwards

Sarah Sell Professor of Pediatrics

Director, Division of Pediatric Clinical Research

Vanderbilt University School of Medicine

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Emil Gotschlich

R. Gwin Follis-Chevron Professor

Laboratory of Bacterial Pathogenesis and Immunology

Rockefeller University


Harry B. Greenberg

Senior Associate Dean for Research and Training

Stanford University School of Medicine

Professor of Medicine (Gastroenterology & Hepatology) Microbiology and Immunology, and Staff Physician VA Palo Alto Health Care System


Diane Griffin

Professor

Alfred and Jill Sommer Professor and Chair in Molecular Microbiology and Immunology

Johns Hopkins Bloomberg School of Public Health


Karl D. Handelsman

Managing Director

CMEA Ventures


David C. Kaslow

Vice President, Infectious Diseases and Vaccines Franchise

Merck Research Laboratories


Karen Midthun

Deputy Director, Center for Biologics Evaluation and Research

Food and Drug Administration


Edward S. Mocarski, Jr.*

Distinguished Fellow, MedImmune Vaccines

MedImmune, AstraZeneca

Professor Emeritus Stanford University

Robert W. Woodruff Professor in the Department of Microbiology and Immunology

Emory Vaccine Center, Emory University


Barbara Mulach

Director, Office of Scientific Coordination and Program Operations

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Stanley Plotkin*

Executive Advisor to CEO, Sanofi Pasteur

Emeritus Professor of Pediatrics, University of Pennsylvania


Leighton Read*

General Partner

Alloy Ventures


Robin Robinson

Director, Biomedical Advanced Research Development Authority

U.S. Department of Health and Human Services


CAPT Rebecca Sheets

Vaccine Scientific and Regulatory Specialist

National Institute of Allergy and Infectious Diseases

National Institutes of Health


Jeffrey Ulmer

Global Head, External Research

Novartis Vaccines and Diagnostics


Justin Wright

Manager, Bio-Analytical Sciences

BD Medical-Pharmaceutical Systems

THIRD NATIONAL STAKEHOLDER MEETING INFORMED VACCINE DECISION MAKING

Monday, February 2, 2009

Keck Center of the National Academies

500 Fifth Street, N.W.

Washington, DC


Please note:

Panelist titles and affiliations are provided at the end of the agenda.

(*) denotes panelists who will provide brief introductory comments at the beginning of a panel

() denotes panelists who contributed to the draft National Vaccine Plan

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

8:30 am

Welcome and Overview of the Agenda and the Day’s Proceedings

Committee Introductions

Claire V. Broome

Institute of Medicine (IOM)

Committee Chair

8:45 am

Panel 1: Who and what informs personal decision making about immunization?

Moderator: Edgar Marcuse, IOM committee member

 

Topics of discussion may include

 

  • Science, values, social norms, credibility of sources, ease of access, access to and comprehension of information, behavioral factors (e.g., risk aversion), opinions of formal or informal community leaders

  • Factors for and against using certain sources of information

  • Preferred sources and information needs of diverse populations (age, ethnicity, etc.)

  • Health care providers, their knowledge, and their role

 

Panelists:

Louis Z. Cooper (Columbia University)

Vicky Debold (National Vaccine Information Center [NVIC])

Julie Downs (Carnegie Mellon)

Lynda Flowers (AARP)

Samuel L. Katz (Duke University)

Julie Leask (University of Sydney)

Anita Manning (Freelance Journalist)

Mairi Breen Rothman (American College of Nurse-Midwives)

Kristine Sheedy(CDC/NCIRD)

 

Questions and comments from the audience

10:30 am

Break

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

10:45 am

Panel 2: The science of communication and good practices in communicating about vaccines and immunization

Moderator: Élaine Chatigny, IOM committee member

 

Topics of discussion may include

 

  • Evidence from social and behavioral sciences

  • Gaps in the available research

 

Panelists:

Julie Downs (Carnegie Mellon)

Julie Leask* (University of Sydney)

Martin G. Myers (NNii)

Rebecca Parkin (George Washington University)

Kristine Sheedy (CDC/NCIRD)

 

Questions and comments from the audience

12:30 pm

Lunch

1:30 pm

Panel 3: Ethical, legal, and policy issues in communicating about immunization

Moderator: Sara Rosenbaum, IOM committee member

 

Topics of discussion may include

 

  • Communicating in the context of policies requiring immunization (e.g., for school entry, for healthcare workforce)

  • How ethical questions and standards influence communication about immunization

 

Panelists:

Barbara Loe Fisher (NVIC)

Ross Silverman (Southern Illinois University)

Christina Tan (N.J. Department of Health)

L.J. Tan (American Medical Association [AMA])

 

Questions and comments from the audience

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

3:15 pm

Break

3:30 pm

Panel 4: Communicating to encourage immunization

Moderator: Richard Mandsager, IOM committee member

 

Topics of discussion may include

 

  • Strengthening the communication activities of public health agencies

  • Lessons to be learned (in general, and from the day’s discussions)

  • Interactions between public health agencies and the media

  • Meeting public needs and expectations

  • Health care providers, their knowledge, and their role

 

Panelists:

Louis Z. Cooper (Columbia University)

Samuel L. Katz (Duke University)

Nancy Lee* (Social Marketing Services, Inc.)

Martin G. Myers (NNii)

Rebecca Parkin (George Washington University)

Glen Nowak (CDC/OEC)

Kristine Sheedy* (CDC/NCIRD)

Dean Sidelinger* (San Diego County Public Health Services)

Christina Tan (N.J. Department of Health)

L.J. Tan (AMA)

5:30 pm

Adjourn

PANELIST TITLES AND AFFILIATIONS

Louis Z. Cooper

Professor Emeritus, Pediatrics

College of Physicians and Surgeons

Columbia University

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Vicky Debold

Director of Patient Safety

National Vaccine Information Center


Julie Downs

Research Scientist

Department of Social and Decision Sciences

Carnegie Mellon University


Lynda Flowers

Strategic Policy Advisor

AARP Public Policy Institute


Samuel L. Katz

Wilburt C. Davison Professor Emeritus of Pediatrics

Duke University


Julie Leask

Senior Research Fellow

National Centre for Immunisation Research and Surveillance

Conjoint Senior Lecturer

Faculty of Medicine

University of Sydney


Nancy Lee

President

Social Marketing Services, Inc.


Barbara Loe Fisher

President and Co-Founder

National Vaccine Information Center


Anita Manning

Freelance Journalist


Martin G. Myers

Executive Director

National Network for Immunization Information (NNii)

Professor of Pediatrics, Preventive Medicine, and Community Health

Associate Director for Public Health Policy and Education

Sealy Center for Vaccine Development

University of Texas Medical Branch

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Glen Nowak

Director

Division of Media Relations

Office of Enterprise Communication

Centers for Disease Control and Prevention


Rebecca Parkin

Associate Dean, Research and Public Health Practice

Professor

Department of Environmental and Occupational Health, and Department of Epidemiology and Biostatistics

School of Public Health and Health Services

George Washington University


Mairi Breen Rothman

Professional Services Consultant

American College of Nurse-Midwives


Kristine Sheedy

Associate Director

Office of Communication Science

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention


Dean Sidelinger

Deputy Public Health Officer

Public Health Services Administration

San Diego County


Ross Silverman

Chair, Medical Humanities

Professor, Medical Humanities and Psychiatry

School of Medicine

Professor, Medical Jurisprudence

School of Law

Director, Program in Law and Health Policy

Southern Illinois University


Christina Tan

State Epidemiologist

New Jersey Department of Health and Senior Services

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

L.J. Tan

Director, Medicine and Public Health

American Medical Association

FOURTH NATIONAL STAKEHOLDER MEETING THE SAFETY OF VACCINES AND VACCINATION PRACTICES

Tuesday, April 14, 2009

Keck Center of the National Academies, Room 100

500 Fifth Street, N.W.

Washington, DC


Please note:

Panelist titles and affiliations are provided at the end of the agenda.

8:30 am

Welcome and Overview of the Agenda and the Day’s Proceedings

Committee Introductions

Claire V. Broome,

Institute of Medicine (IOM)

Committee Chair

8:45 am

Panel 1: Identifying vaccine safety concerns

Moderator: Grace Lee, IOM committee member

 

Topics of discussion may include

  • Assessing safety in pre-licensure clinical trials (Phase I-III)

  • Safety objectives pre-licensure versus post-licensure

  • Gaps in the detection of safety signals and how to address them

  • Vaccine Adverse Events Reporting System

  • Active surveillance capabilities of the Vaccine Safety Datalink

 

Participants:

Robert Ball, FDA

Louis Z. Cooper, Columbia University

Adrian Dana, Merck

Vicky Debold, NVIC

Susan Ellenberg, University of Pennsylvania

Neal Halsey, Johns Hopkins University

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Florence Houn, Celgene

Phillip Krause, FDA

Lanie Friedman Ross, University of Chicago

Thomas M. Vernon, Sanofi Pasteur

Melinda Wharton, CDC/Immunization Safety

Office (ISO)

 

Questions and comments from the audience

10:30 am

Break

10:45 am

Panel 2: Studying vaccine safety

Moderator: Art Reingold, IOM committee member

 

Topics for discussion may include

  • What triggers switching from surveillance to evaluation of a safety signal

  • Evaluating safety signals, assessing potential causality of an observed adverse event

  • Approaches and methodological, ethical, and practical advantages and challenges

  • Assessing the relationship between immunization and diagnostic categories (e.g., demyelinating diseases, rheumatologic diseases)

  • Vaccine Safety Datalink and Clinical Immunization Safety Assessment network challenges and opportunities

  • Enhancing timeliness of conducting and completing studies (tools such as rapid cycle analysis)

  • Gaps in vaccine safety science

 

Participants:

Robert Ball, FDA

Sean Hennessy, University of Pennsylvania

John Iskander, CDC/ISO

Samuel L. Katz, Duke University

Tracy Lieu, Harvard University

Andy Pavia, University of Utah, NVAC Vaccine Safety WG

Lanie Friedman Ross, University of Chicago

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Kenneth J. Rothman, RTI International Patricia Saddier, Merck

Brian Strom, University of Pennsylvania

Melinda Wharton, CDC/ISO

 

Questions and comments from the audience

12:30 pm

Lunch

1:30 pm

Update from the National Vaccine Advisory Committee Safety Working Group

Andy Pavia, NVAC working group chair

1:45 pm

Panel 3: Basic science (in vivo, in vitro, and human clinical models)

Moderator: Claire V. Broom, IOM Committee

Chair

 

Topics for discussion may include

  • Current research on host risk factors, gaps

  • Genetic contributions to immune response

  • Adequacy of animal models for studying vaccine responses

  • Exploring the role of adjuvants in adverse reactions to vaccines

  • Gaps in understanding of immune system (immune response to vaccines, the immature immune system, etc.)

 

Participants:

George Curlin, NIH/NIAID

Kathy Edwards, Vanderbilt University

Charles Hackett, NIH/NIAID

Neal Halsey, Johns Hopkins University

Ruth Karron, Johns Hopkins University

Phillip Krause, FDA

 

Questions and comments from the audience

3:15 pm

Break

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

3:30 pm

Panel 4: Policy issues related to vaccine safety and compensation for vaccine injuries

Moderator: Sara Rosenbaum, IOM committee member

 

Topics for discussion may include

  • Vaccine safety as conceived in the 1986 act that established the Vaccine Injury Compensation Program

  • Implications of recent decisions of the U.S. Court of Federal Claims

 

Participants:

Louis Z. Cooper, Columbia University

Barbara Loe Fisher, NVIC

Anthony Robbins, Tufts University

Jeff Sconyers, Seattle Children’s Hospital, outgoing chair ACCV

Tim Westmoreland, Georgetown University

 

Questions and comments from the audience

5:15 pm

Closing comments

5:30 pm

Adjourn

PANELIST TITLES AND AFFILIATIONS

Robert Ball

Chief, Vaccine Safety Branch

Division of Epidemiology

Food and Drug Administration


George Curlin

Medical Officer

Office of the Director

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Louis Z. Cooper

Professor Emeritus, Pediatrics

College of Physicians and Surgeons

Columbia University


Adrian Dana

Senior Director

Clinical Risk Management and Safety Surveillance

Merck Research Labs


Vicky Debold

Director of Patient Safety

National Vaccine Information Center


Kathryn Edwards

Sarah Sell Professor of Pediatrics

Director, Division of Pediatric Clinical Research

Vanderbilt University School of Medicine


Susan Ellenberg

Professor of Biostatistics

Associate Dean for Clinical Research

University of Pennsylvania School of Medicine


Barbara Loe Fisher

President and Co-founder

National Vaccine Information Center


Charles Hackett

Deputy Director

Division of Allergy, Immunology, and Transplantation

National Institute of Allergy and Infectious Diseases

National Institutes of Health


Neal Halsey

Professor

Department of International Health, Disease Prevention & Control

Department of Pediatrics

Johns Hopkins University

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Sean Hennessy

Senior Scholar, Epidemiology

Center for Clinical Epidemiology and Biostatistics

Assistant Professor of Epidemiology, University of Pennsylvania School of Medicine

Assistant Professor of Pharmacology, Department of Pharmacology

Director of Ambulatory Drug Use and Effects, University of Pennsylvania Medical Center


Florence Houn

Vice President, Regulatory Affairs

Celgene Corporation


John Iskander

Associate Director for Immunization Safety

Centers for Disease Control and Prevention


Ruth Karron

Director, Center for Immunization Research

Director, Johns Hopkins Vaccine Initiative

Johns Hopkins University


Samuel L. Katz

Wilburt C. Davison Professor Emeritus of Pediatrics

Duke University


Phillip Krause

Laboratory Chief

Lead Research Investigator

Center for Biologics Evaluation and Research

Food and Drug Administration


Tracy Lieu

Professor

Director of Faculty Development

Director, Center for Child Health Care Studies

Department of Ambulatory Care and Prevention

Harvard Pilgrim Health Care and Harvard Medical School

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Andy Pavia

Professor, Division of Infectious Diseases

University of Utah School of Medicine

Chair, Vaccine Safety Working Group, National Vaccine Advisory Committee


Anthony Robbins

Professor

Department of Public Health and Family Medicine

Tufts University


Lanie Friedman Ross

Carolyn and Matthew Bucksbaum Professor of Clinical Ethics

Professor, Departments of Pediatrics, Medicine, and Surgery

Associate Director, MacLean Center for Clinical Medical Ethics

University of Chicago


Kenneth J. Rothman

Distinguished Fellow in Epidemiology

Vice President, Epidemiology Research

RTI International


Patricia Saddier

Senior Director, Epidemiology Department

Merck Research Laboratories


Jeff Sconyers

Senior Vice President and General Counsel

Seattle Children’s Hospital

Chair, Advisory Commission on Childhood Vaccines


Brian Strom

George S. Pepper Professor of Public Health and Preventive Medicine

Departments of Biostatistics and Epidemiology

University of Pennsylvania


Thomas M. Vernon

Consultant with Sanofi Pasteur

Former VP, Merck Vaccine Division

Former Executive Director, Colorado Department of Health

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Tim Westmoreland

Visiting Professor of Law

Georgetown University


Melinda Wharton

Deputy Director

National Center for Immunizations and Respiratory Diseases

Centers for Disease Control and Prevention


Some federal agencies contributed to the development of the draft strategic National Vaccine Plan

FIFTH NATIONAL STAKEHOLDER MEETING VACCINES AND GLOBAL HEALH

Thursday, June 4, 2009

The Seattle Public Library

1000 Fourth Avenue

Seattle, Washington


Please note:

Complete participant affiliations are provided at the end of the agenda.

8:30 am

Welcome, Overview, and Committee Introductions

Claire V. Broome, IOM Committee Chair

8:45 am

Panel 1: Development of new vaccines and those needed for global use

Moderator: Claire Broome, IOM Committee Chair

 

Topics of discussion may include

  • Setting priorities

  • Scientific challenges

  • Regulatory issues

  • Implementation issues

  • Advocacy or policy communication issues

  • Role of non-Western vaccine companies as vaccine developers and suppliers for both developed and developing nations

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Discussants:

Norman Baylor, CBER/FDA (by phone)

Brent Burkholder, NCIRD/CDC

Thomas Cherian, World Health Organization (WHO)

Mark Feinberg, Merck

John Ferguson, Novartis Vaccines & Diagnostics

Orin Levine, Johns Hopkins University

Adel Mahmoud, Princeton University (by phone)

Margaret McCluskey, U.S. Agency for International Development (USAID)

Regina Rabinovich, Gates Foundation

Jerald Sadoff, Aeras Global TB Vaccine Foundation

Theodore Tsai, Novartis

Justin Wright, BD Medical-Pharmaceutical Systems

10:30 am

Break

10:45 am

Panel 2: Immunization program issues: Infrastructure, communication, impact of eradication or elimination

Moderator: Milagritos Tapia, IOM committee member

 

Topics of discussion may include

  • Quality and safety of administration, storage, inventory management, cold chain, other infrastructure issues

  • Impact of health systems “reform”

  • Are vaccines reaching those at highest risk of disease?

  • Innovative approaches to target high-risk or hard-to-reach groups

  • Implications of target populations with high proportion of HIV infected

 

Discussants:

Brent Burkholder, NCIRD/CDC

Thomas Cherian, WHO

Rod Hausser, BD Medical-Pharmaceutical Systems

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

Orin Levine, Johns Hopkins University

Margaret McCluskey, USAID

Robert Steinglass, John Snow Inc.

Linda Venczel, Gates Foundation

12:30 pm

Lunch

1:30 pm

Panel 3: Surveillance of safety, effectiveness, coverage, disease

Moderator: Art Reingold, IOM committee member

 

Topics of discussion may include

  • Immunization program monitoring and evaluation

  • Coverage measurement versus disease impact

  • Challenges of safety monitoring (e.g., yellow fever vaccine in Africa)

 

Discussants:

Brent Burkholder, NCIRD/CDC

John Ferguson, Novartis Vaccines & Diagnostics

David Fleming, Director & Health Officer, WA

Kathy Neuzil, Program for Appropriate

Technology in Health (PATH)

Robert Steinglass, John Snow Inc.

Linda Venczel, Gates Foundation

3:15 pm

Break

3:30 pm

Panel 4: Financing vaccine development and purchase

Moderator: David Paltiel, IOM committee member

 

Topics of discussion may include

  • Financing new vaccine development

  • Financing purchase of expensive new vaccines (e.g., pneumococcal conjugate, human papilloma virus)

  • Sustainable support for new vaccines by developing countries

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

 

  • Experience with novel financing approaches—International Financing Facility for Immunization (IFFIm), Advance Market Commitment (AMC), Gates (pros and cons)

  • Prioritizing support for optimal use of existing vaccines versus development of new vaccines

 

Discussants:

Brent Burkholder, NCIRD/CDC

Orin Levine, Johns Hopkins University

Melinda F. Moree, Global Health Services

Regina Rabinovich, Gates Foundation

Jerald Sadoff, Aeras Global TB Vaccine Foundation

5:30 pm

Adjourn

PANELIST TITLES AND AFFILIATIONS

Jon Kim Andrus

Professor, Department of Global Health Director, Global Health MPH Program

George Washington University


Norman Baylor

Director, Office of Vaccines Research and Review

Center for Biologics Evaluation and Research

Food and Drug Administration


Brent Burkholder

Director, Global Immunization Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention


Thomas Cherian

Coordinator

Expanded Programme on Immunization

Department of Immunization, Vaccines and Biologicals

World Health Organization

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Mark Feinberg

Vice President, Medical Affairs and Policy

Merck Vaccines and Infectious Diseases

Merck & Co., Inc.


John Ferguson

Vice President and Global Head

Pharmacovigilance & Medical Safety

Novartis Vaccines & Diagnostics


David Fleming

Director and Health Officer

Department of Public Health

Seattle/King County


Rod Hausser

Director

Business Development and Operations

BD Medical-Pharmaceutical Systems


Orin Levine

Executive Director, PneumoADIP

Associate Professor, International Health

Johns Hopkins University


Adel Mahmoud

Woodrow Wilson School of Public and International Affairs

Department of Molecular Biology

Princeton University


Margaret McCluskey

Senior Technical Advisor, HIV Vaccines

GH/Office of HIV & AIDS

U.S. Agency for International Development


Melinda F. Moree

Vice President, Global Health Services


Kathy Neuzil

Director, Influenza Vaccine Project

Clinical Director, Rotavirus Vaccine Program

PATH

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×

Regina Rabinovich

Director, Infectious Diseases Development

Global Health Program

The Bill & Melinda Gates Foundation


Jerald Sadoff

President and Chief Executive Officer

Aeras Global TB Vaccine Foundation


Robert Steinglass

Technical Director, IMMUNIZATIONBasics Project

John Snow Inc.


Theodore Tsai

Senior Vice President, Scientific Affairs

Novartis


Linda Venczel

Vaccine-Preventable Diseases

Integrated Health Systems Development

The Bill & Melinda Gates Foundation


Justin Wright

Manager, Bio-Analytical Sciences

BD Medical-Pharmaceutical Systems

Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 317
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 318
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 319
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 320
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 321
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 322
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 323
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 324
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 325
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 326
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 327
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 328
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 329
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 330
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 331
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 332
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 333
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 334
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 335
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 336
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 337
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 338
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 339
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 340
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 341
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 342
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 343
Suggested Citation:"Appendix F: Agendas of Stakeholder Meetings Held by the Committee on Review of Priorities in the National Vaccine Plan (July 2008-June 2009)." Institute of Medicine. 2010. Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press. doi: 10.17226/12796.
×
Page 344
Next: Appendix G: Acronyms »
Priorities for the National Vaccine Plan Get This Book
×
Buy Paperback | $67.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccination is a fundamental component of preventive medicine and public health. The use of vaccines to prevent infectious diseases has resulted in dramatic decreases in disease, disability, and death in the United States and around the world. The current political, economic, and social environment presents both opportunities for and challenges to strengthening the U.S. system for developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services.

Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. The book makes recommendations about priority actions in the update to the National Vaccine Plan that are intended to achieve the objectives of disease prevention and enhancement of vaccine safety. It is centered on the plan's five goals in the areas of vaccine development, safety, communication, supply and use, and global health.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!